HealthUnited States
FDA's mRNA Flu Vote Is Really a Test of Whether Faster Vaccines Can Still Win Trust
Federal advisers unanimously backed Moderna's mFlusiva on June 18, 2026, but the larger health story is whether faster flu-vaccine manufacturing can matter before trust gaps and late-season mismatch do the talking for everyone else.